Laura Holzer, MD
Internal Medicine · Menifee, CANPI 1972862092
Payments from drug & device makers
Across 85 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$159
- AbbVie$153
- Novo Nordisk$132
- Pfizer$110
- GSK$107
- Lilly USA, LLC$92
- plus $699 from 24 others
What the payments were for
- Food & beverage$1,453100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 14 | $159 |
| AbbVie(2 entities) | 9 | $153 |
| Novo Nordisk | 8 | $132 |
| Pfizer | 6 | $110 |
| GSK | 6 | $107 |
| Lilly USA, LLC | 5 | $92 |
| Viatris Specialty LLC | 3 | $58 |
| Eisai Inc. | 2 | $55 |
| Antares Pharma, Inc. | 3 | $54 |
| Edwards Lifesciences | 2 | $46 |
| Merck | 3 | $43 |
| Exact Sciences | 2 | $43 |
| Astellas Pharma US Inc | 2 | $38 |
| Amgen(2 entities) | 2 | $35 |
| Boehringer Ingelheim | 2 | $32 |
| Seqirus USA Inc | 2 | $30 |
| Almatica Pharma LLC | 1 | $29 |
| Mylan Specialty L.p. | 1 | $25 |
| Abbott | 1 | $23 |
| AstraZeneca | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Biogen | 1 | $21 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $18 |
| Evoke Pharma, Inc. | 1 | $18 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $14 |
| Novartis | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
How this compares
$1,453 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 181 | $170,534 |
| MounjaroTirzepatide | 119 | $134,835 |
| OzempicSemaglutide | 76 | $88,105 |
| JardianceEmpagliflozin | 39 | $54,485 |
| XareltoRivaroxaban | 58 | $47,234 |
| RybelsusSemaglutide | 14 | $32,721 |
| TrulicityDulaglutide | 23 | $30,671 |
| MyrbetriqMirabegron | 40 | $30,425 |
| LinzessLinaclotide | 34 | $20,804 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $18,054 |
| Tresiba Flextouch U-100Insulin Degludec | 26 | $18,036 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $17,282 |
| JanuviaSitagliptin Phosphate | 13 | $17,192 |
| FarxigaDapagliflozin Propanediol | 13 | $15,784 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 19 | $13,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $110 | $170,534181 claims |
| Lilly USA, LLCMounjaro, Trulicity | $92 | $165,506142 claims |
| Novo NordiskOzempic, Rybelsus | $132 | $120,82590 claims |
| Boehringer IngelheimJardiance | $32 | $54,48539 claims |
| Johnson & JohnsonXarelto | $159 | $47,23458 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $107 | $30,70758 claims |
| Astellas Pharma US IncMyrbetriq | $38 | $30,42540 claims |
| AbbVieLinzess, Synthroid | $153 | $25,300106 claims |
| MerckJanuvia | $43 | $17,19213 claims |
| AstraZenecaFarxiga | $22 | $15,78413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Menifee
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.